Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Pro Medicus Limited ( (AU:PME) ) is now available.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. As of November 11, 2025, the company has repurchased a total of 19,393 ordinary fully paid securities, including 3,902 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$283.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging software and services primarily for medical professionals and institutions. The company focuses on delivering innovative solutions that enhance diagnostic capabilities and streamline medical imaging processes.
YTD Price Performance: 1.20%
Average Trading Volume: 181,061
Technical Sentiment Signal: Buy
Current Market Cap: A$26.4B
Learn more about PME stock on TipRanks’ Stock Analysis page.